var data={"title":"C1 esterase inhibitor, concentrate from human plasma: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">C1 esterase inhibitor, concentrate from human plasma: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/367710?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=c1-esterase-inhibitor-concentrate-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">see &quot;C1 esterase inhibitor, concentrate from human plasma: Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=c1-esterase-inhibitor-concentrate-from-human-plasma-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;C1 esterase inhibitor, concentrate from human plasma: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6759053\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Berinert;</li>\n      <li>Cinryze;</li>\n      <li>Haegarda</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13261898\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Berinert;</li>\n      <li>Cinryze;</li>\n      <li>Haegarda</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6761341\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Blood Product Derivative;</li>\n      <li>\n        C1 Esterase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764794\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hereditary angioedema (HAE) attacks, routine prophylaxis</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cinryze</b>: IV: 1,000 units every 3 to 4 days; doses &le;2,500 units (&le;100 units/kg) every 3 or 4 days may be considered based on individual patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Haegarda:</b> SubQ: 60 units/kg every 3 or 4 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HAE attacks (abdominal, facial or laryngeal), treatment (Berinert):</b> IV: 20 units/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764793\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=c1-esterase-inhibitor-concentrate-from-human-plasma-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;C1 esterase inhibitor, concentrate from human plasma: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hereditary angioedema (HAE) attacks, routine prophylaxis (Cinryze, Haegarda):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HAE attacks (abdominal, facial or laryngeal), treatment (Berinert):</b> Children and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764795\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682372\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682373\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764799\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Berinert: 500 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cinryze: 500 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Haegarda: 2000 units (1 ea); 3000 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764774\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28604067\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kit, Intravenous:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Berinert: 1,500 units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11368727\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Assistance with procurement and reimbursement of Cinryze is available for health care providers and patients through the CINRYZESolutions program (telephone:1-877-945-1000) or at http://www.cinryze.com/Cinryze_Solutions/Default.aspx</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764796\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Berinert (500 units): Administer intravenously at ~4 mL/minute by a separate infusion line.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Berinert (1,500 units) [Canadian product]: Administer intravenously by slow injection by a separate infusion line.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cinryze (500 units): Administer intravenously at 1 mL/minute; (as a guideline, administer 1,000 units over 10 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Haegarda (2,000 or 3,000 units): For SubQ injection only in the abdominal area or other SubQ injection sites. Rotate injection sites.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Self-administration: Following patient training and instructions on self-administration, patient may self-administer treatment (Berinert) or prophylaxis (Cinryze, Haegarda) therapy. Epinephrine should be available during self-administration in the event of an acute, severe hypersensitivity reaction. Patient suffering from an acute laryngeal hereditary angioedema (HAE) attack and self-administering should be informed to seek immediate medical attention following treatment (potential for airway obstruction to occur).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A silicone-free syringe may be required for administration (refer to manufacturer's labeling).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764775\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hereditary angioedema:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Berinert: Treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adults and pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cinryze, Haegarda: Routine prophylaxis against angioedema attacks in adults and adolescents with HAE.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764784\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (35%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distress, abdominal pain, dysgeusia, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (7%), angioedema (including exacerbation of hereditary angioedema)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Fungal infection (vulvovaginal), viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever, infusion-related reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, anxiety, cerebrovascular accident, chest pain, chills, deep vein thrombosis, diarrhea, fatigue, malaise, migraine, pain, shock, sinusitis, swelling, thrombosis, transient ischemic attacks, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764780\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of anaphylactic or life-threatening hypersensitivity reactions to human C1 inhibitor or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764781\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe hypersensitivity reactions (eg, urticaria, hives, tightness of the chest, wheezing, hypotension, anaphylaxis) may occur during or after administration. Signs/symptoms of hypersensitivity reactions may be similar to the attacks associated with hereditary angioedema, therefore, consideration should be given to treatment methods. In the event of acute or severe hypersensitivity reactions, discontinue treatment immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Serious arterial and venous thromboembolic events have been reported at recommended intravenous doses and when used off-label at doses higher than recommended. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Consider potential risk of thrombosis with use, and closely monitor patients with preexisting risks for thrombotic events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents (eg, viruses, the variant Creutzfeldt-Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent) that could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-administration: Due to the potential for airway obstruction, patients suffering from an acute laryngeal hereditary angioedema (HAE) attack and self-administering should be informed to immediately seek medical attention following treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298919\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764785\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8998&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the thrombogenic effect of C1 inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May enhance the thrombogenic effect of C1 inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May enhance the thrombogenic effect of C1 inhibitors.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764777\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764778\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Although information related to use during pregnancy is limited, plasma-derived human C1 inhibitor concentrate is the preferred treatment for HAE during pregnancy (Baker 2013; Caballero 2012). Women with HAE should be monitored closely during pregnancy and for at least 72 hours after delivery (Caballero 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21099198\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if C1 inhibitor is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Lactation may increase the frequency of attacks, and women should be monitored closely. Plasma-derived human C1 inhibitor concentrate is the preferred treatment for hereditary angioedema (HAE) during lactation (Caballero 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23907080\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs/symptoms of hypersensitivity reactions and thrombotic events.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764789\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">C1 inhibitor, one of the serine proteinase inhibitors found in human blood, plays a role in regulating the complement and intrinsic coagulation (contact system) pathway, and is also involved in the fibrinolytic and kinin pathways. C1 inhibitor therapy in patients with C1 inhibitor deficiency, such as HAE, is believed to suppress contact system activation via inactivation of plasma kallikrein and factor XIIa, thus preventing bradykinin production. Unregulated bradykinin production is thought to contribute to the increased vascular permeability and angioedema observed in HAE.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764790\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Cinryze: Increased plasma C1 inhibitor levels observed ~1 hour or less</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of symptom relief: Berinert: Median: 15 minutes per attack; Cinryze: Pediatric patients 6 to 17 years: Median: 30 minutes per attack; for the majority of patient unequivocal symptom relief reported within 1 hour (range: 15 to 135 minutes) (Lumry 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: Time to complete resolution of hereditary angioedema (HAE) symptoms: Berinert: Median: 8.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Berinert: V<sub>ss</sub>: Children and Adolescents: (6 to 13 years, n=5): 0.02 L/kg (range: 0.017 to 0.026 L/kg); Adults: 0.018 L/kg (range: 0.011 to 0.028 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Haegarda: V<sub>d</sub>: Adolescents and Adults: 0.05 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Haegarda: 42.7%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Berinert:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (6 to 13 years, n=5): 22 hours (range: 20 to 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults (following a single dose): 22 hours (range: 17 to 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cinryze: Adults: 56 hours (range: 11 to 108 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Haegarda: Adolescents and Adults: 69 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Cinryze: ~4 hours; Haegarda: 59 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321852\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Berinert Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (1): $3,378.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cinryze Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (1): $3,310.55</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Haegarda Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (1): $2,256.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (1): $3,384.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23672322\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Berinert (AT, AU, BE, CH, CY, CZ, DK, ES, FI, FR, GB, HU, IL, KR, LU, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR);</li>\n      <li>Berinert P (AR, JP);</li>\n      <li>Cinryze (CZ, DK, EE, GB, IS, LT, MT, NO, PL, SE, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Baker JW, Craig TJ, Riedl MA, et al. Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. <i>Allergy Asthma Proc.</i> 2013;34(2):162-169.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/c1-esterase-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/23484892/pubmed\" target=\"_blank\" id=\"23484892\">23484892</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berinert (C1 Esterase Inhibitor [Human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berinert (C1 Esterase Inhibitor [Human]) [product monograph]. Ottawa, Ontario, Canada: CSL Behring Canada Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. <i>J Allergy Clin Immunol.</i> 2012;129(2):308-320.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/c1-esterase-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/22197274/pubmed\" target=\"_blank\" id=\"22197274\">22197274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cicardi M, Zingale L. How do we treat patients with hereditary angioedema. <i>Transfus Apher Sci. </i>2003;29(3):221-227.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/c1-esterase-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/14572813/pubmed\" target=\"_blank\" id=\"14572813\">14572813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cinryze (C1 esterase inhibitor [human]) [prescribing information]. Lexington, MA: Shire ViroPharma Biologics; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cinryze (C1 inhibitor [human]) [Canadian product monograph]. Lexington, MA, USA: ViroPharma Biologics Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farkas H, Jakab L, Temesszentandrasi G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. <i>J Allergy Clin Immunol.</i> 2007;120(4):941-947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/c1-esterase-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/17761272/pubmed\" target=\"_blank\" id=\"17761272\">17761272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frank MM, Jiang H. New therapies for hereditary angioedema: disease outlook changes dramatically. <i>J Allergy Clin Immunol.</i> 2008;121(1):272-280.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/c1-esterase-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/18206518/pubmed\" target=\"_blank\" id=\"18206518\">18206518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haegarda (C1 Esterase Inhibitor [Human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haegarda (C1 Esterase Inhibitor [Human]) [prescribing information]. Ottawa, Ontario, Canada: CSL Behring Canada Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hermans C, &ldquo;Successful Management With C1-Inhibitor Concentrate of Hereditary Angioedema Attacks During Two Successive Pregnancies: A Case Report,&rdquo; <i>Arch Gynecol Obstet</i>, 2007, 276(3):271-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/c1-esterase-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/17653743/pubmed\" target=\"_blank\" id=\"17653743\">17653743</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lumry W, Manning ME, Hurewitz DS, et al, &quot;Nanofiltered C1-Esterase Inhibitor for the Acute Management and Prevention of Hereditary Angioedema Attacks Due to C1-Inhibitor Deficiency in Children,&quot; <i>J Pediatr</i>, 2013, 162(5):1017-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/c1-esterase-inhibitor-concentrate-from-human-plasma-drug-information/abstract-text/23312695/pubmed\" target=\"_blank\" id=\"23312695\">23312695</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8998 Version 120.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6759053\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13261898\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F6761341\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6764794\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F6764793\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F6764795\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15682372\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682373\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6764799\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F6764774\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F28604067\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11368727\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6764796\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6764775\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6764784\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6764780\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6764781\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298919\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6764785\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F6764777\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6764778\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21099198\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F23907080\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6764789\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F6764790\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321852\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23672322\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8998|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=c1-esterase-inhibitor-concentrate-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">C1 esterase inhibitor, concentrate from human plasma: Patient drug information \t</a></li><li><a href=\"topic.htm?path=c1-esterase-inhibitor-concentrate-from-human-plasma-pediatric-drug-information\" class=\"drug drug_pediatric\">C1 esterase inhibitor, concentrate from human plasma: Pediatric drug information</a></li></ul></div></div>","javascript":null}